c-erbB-2 protein in serum of primary lung cancer patients

Cancer Detection and Prevention

Volumn 26, Issue 1, 2002, Pages 64-68

  Filiberti, Rosa ^a   Marroni, Paola ^a   Paganuzzi, Michela ^a   Izzo, Valeria ^a   Padovani, Paola ^a   Cafferata, Mara ^a   Ardizzoni, Andrea ^a   Neri, Monica ^a   Raimondi, Luigi ^a   Puntoni, Riccardo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

c erbB 2; Lung cancer; Oncoprotein; Tumor marker

Indexed keywords

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 0036951944     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(02)00014-4     Document Type: Article

References (47)

1. Mulshine JL, Treston AM, Brown P, et al. Initiators and promoters of lung cancer. Chest 1993;103:4S-11S.
2. Semba K, Kamata N, Toyoshima K, et al. A v-erb-B-related protooncogene, c-erbB-2, is distinct from c-erbB-1/epidermal growth factor receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 1985;82:6497-501.
3. Yokota J, Yamamoto T, Toyoshima K, et al. Amplification of the c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1986;15:765-6.
4. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
5. Yamamoto T, Ikawa S, Akijama T, et al. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 1986;319:230-4.
6. Lin YJ, Clinton GM. A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene 1991;6:639-43.
7. Pupa SB, Menard S, Morelli D, et al. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolitic cleavage. Oncogene 1993;8:2917-23.
8. Kynast B, Binder L, Marx D, et al. Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients. J Cancer Res Clin Oncol 1993;119:249-52.
9. Okada N, Ohshio G, Yamaki K, et al. Elevated serum c-erbB-2 protein levels in patients with pancreatic cancer: correlation to metastasis and shorter survival. Oncology 1995;52:392-6.
10. Vogel W, Kath R, Kosmehl H, et al. The neu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas. J Cancer Res Clin Oncol 1996;122:118-21.
11. Motoo Y, Sawabu N, Yamaguchi Y, et al. Serum levels of c-erbB-2 protein in digestive diseases. J Gastroenterol 1994;29:616-20.
12. Meden H, Marx D, Fattahi A, et al. Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. J Res Clin Oncol 1994;20:378-81.
13. Rasmuson T, Grankvist K, Ljungberg B. Soluble ectodomain of c-erbB-2 oncoprotein in relation to tumour stage and grade in human renal cell carcinoma. Br J Cancer 1997;75:1674-7.
14. Breuer B, DeVivo I, Luo JC, et al. erbB-2 and myc oncoproteins in sera and tumors of breast cancer patients. Cancer Epidemiol Biomarkers Prev 1994;3:63-6.
15. Kandl H, Seymour L, Bezwoda WR. Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 1994;70:739-42.
16. Molina R, Jo J, Filella X, et al. c-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer: utility in prognosis. Anticancer Res 1996;16:2295-300.
17. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997;15:2858-65.
18. 185HerbB-2/neu) in human non-small cell carcinomas of the lung. Cancer Res 1990;50:421-31.
19. Sozzi G, Miozzo M, Tagliabue E, et al. Cytogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients. Cancer Res 1991;1:400-4.
20. Tateishi M, Iahida T, Mitsudomi T, et al. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 1991;7:1372-5.
21. Rachwal WJ, Bongiorno PF, Orringer MB, et al. Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. Br J Cancer 1995;72:56-64.
22. Giatromanolaki A, Gorgoulis V, Chetty R, et al. c-erbB-2 oncoprotein expression in operable non-small cell lung cancer Anticancer Res 1996;16:987-94.
23. Pfeiffer P, Clausen PP, Andersen K, et al. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185 HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 1996;74:86-91.
24. Brandt-Rauf PW, Luo JC, Carney WP, et al. Detection of increased amounts of the extracellular domain of the c-erbB-2 oncoprotein in serum during pulmonary carcinogenesis in humans. Int J Cancer 1994;56:383-6.
25. WHO. Histological typing of lung tumors. Am J Clin Pathol 1982;77:123-136.
26. Mountain CF. A new international staging system for lung cancer. Chest 1986;89(Suppl):225-33.
27. McKenzie SJ, Mraks PJ, Lain T, et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 1989;4:543-8.
28. Nugent A, McDermott E, Duffy K, et al. Enzyme-linked immunosorbent assay of c-erbB-2 oncoprotein in breast cancer Clin Chem 1992;38:1471-4.
29. Wu JT, Astill ME, Zhang P. Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers. J Clin Lab Annal 1993;7:31-40.
30. Molina R, Jo J, Filella X, et al. Serum levels of c-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumour Biol 1997;18:188-96.
31. McKenzie SJ, De Sombre KA, Bast BS, et al. Serum levels of HER-2 neu (c-erbB-2) correlate with overexpression of p185 neu in human ovarian cancer. Cancer 1993;71:3942-6.
32. Breuer B, Smith S, Thor A, et al. erbB-2 protein in sera and tumors of breast cancer patients. Breast Cancer Res Treat 1998;49:261-70.
33. Isola JJ, Holli K, Oksa H, et al. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 1994;73:652-8.
34. Schonborn I, Zschiesche W, Spitzer E, et al. c-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk. Breast Cancer Res Treat 1994;29:287-95.
35. Volas GH, Leitzel K, Teramoto Y, et al. Serial serum c-erbB-2 levels in patients with breast carcinoma. Cancer 1996;78:267-72.
36. Osaki T, Mitsudomi T, Oyama T, et al. Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest 1995;108:157-62.
37. Partanen R, Koskinen H, Oksa P, et al. Serum oncoproteins in asbestosis patients. Clin Chem 1995;41:1844-7.
38. Lahat N, Froom P, Kristal-Boneh E, et al. Increased serum concentration of growth factor receptors and Neu in workers previously exposed to asbestos. Occup Environ Med 1999;56:114-7.
39. Krajewska B, Lutz W, pilacik B. Determination of blood serum oncoprotein NEU and anti-oncoprotein p53 - molecular biomarkers in various types of occupational exposure. Int J Occup Med Environ Health 1998;11:343-8.
40. Mielke S, Meden H, Raab T, et al. Effects of interfering and influencing factors on the analyses of p105 (c-erbB-2/HER-2) oncoprotein fragment in serum. Anticancer Res 1997;17:3125-7.
41. Guinee Jr DG, Travis WD, Trivers GE, et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and c-erbB-2 expression. Carcinogenesis 1995;16:993-1002.
42. Diez M, Pollan M, Maestro M, Torres A, Ortega D, Gomez A, et al. Prediction of recurrence by quantification of p185neu protein in non-small cell lung cancer tissue. Br J Cancer 1997;75:684-9.
43. Kern JA, Schwartz DA, Nordberg JE, et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990;50:5184-91.
44. Harpole DH, Herndon JE, Wolfe WG, et al. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995;55:51-6.
45. Kim YC, Park KO, Kern JA, et al. The interactive effect of Ras, HER-2, p53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 1998;22:181-90.
46. Hsieh CC, Chow KC, Fahn HJ. et al. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Ann Thorac Surg 1998;66:1159-63.
47. Greatens TM, Niehans GA, Rubins JB, et al. Do molecular markers predict survival in non-small-cell lung cancer. Am J Respir Crit Care Med 1998;157:1093-7.